Global Pharmaceutical Continuous Manufacturing

Pharmaceutical Continuous Manufacturing Comprehensive Study by Type (Integrated Systems, End to End Systems), Application (API manufacturing, Final Drug Development), End Use (Pharmaceutical Companies, Contract Manufacturing Companies, Research Institutes) Players and Region - Global Market Outlook to 2026

Pharmaceutical Continuous Manufacturing Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Pharmaceutical Continuous Manufacturing?
Continuous pharmaceutical manufacturing proceed for drug developments and API manufacturing. This continuous manufacturing process starts from the processing of basic ingredients to the final product with no need to stop during production. It is mean that there no need to shut down or stop the equipment’s thus, drug is created in zero down time. Continuous manufacturing is also known as Process Manufacturing which operates 24/7. The main aim of the continuous manufacturing flow is to manufacture or process materials on continuous basis. This manufacturing is more time-efficient, which decreases energy requirements and surge productivity. This all benefits of continuous pharmaceutical manufacturing reduces overall waste and cost of production. Further, it reduces risk of human error as few people are involved in continuous processing from start to finish. In pharmaceutical industry, Continuous manufacturing gaining new approach for the production of oral solid dosage (OSD) to fulfil the industry’s demands for rapid product development. Industry demands for higher yields with least waste and human error. Thus continuous pharmaceutical manufacturing is more efficient than batch production. In addition, governments and regulatory bodies are progressively supporting for continuous manufacturing owing its unique feature. In December 2016, The United States passed the 21st Century Cures Act, which promoted advanced pharmaceutical manufacturing which has led much of the drive for continuous manufacturing and also provided funding of USD 4.9 million to support the use of continuous manufacturing techniques for pharmaceuticals.

The market study is broken down by Type (Integrated Systems and End to End Systems), by Application (API manufacturing and Final Drug Development) and major geographies with country level break-up.

There are various companies are operating in the market to provide continue pharmaceutical manufacturing. Increased demand for industrial use is impacting on the demand for continue pharmaceutical manufacturing in positive manner. Hence to grab the opportunity associated with the market, many new market players are entering to the market. The market leaders are investing on organic and non-organic strategic growth initiatives to become dominant in this industry. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Korsch AG (Germany), GEA Group AG (Germany), Siemens AG (Germany), Thermo Fisher Scientific Inc. (United States), Corning Life Sciences(United States), Coperion GmbH (Germany), Gebrüder Lödige Maschinenbau GmbH (Germany), Scott Equipment Company (United States), Baker Perkins Ltd. (United Kingdom), S K Biotek ltd (United States) and Sturtevant, Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Continuus Pharmaceutical (United States) and Glatt GmbH (Germany).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Pharmaceutical Continuous Manufacturing market by Type, Application and Region.

On the basis of geography, the market of Pharmaceutical Continuous Manufacturing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End Use, the sub-segment i.e. Pharmaceutical Companies will boost the Pharmaceutical Continuous Manufacturing market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

In March 2021, Emerson has established partnership with IMA Active. IMA Active is a manufacturer of solid dose processing. This partnership is mainly for developing new solutions to control continuous manufacturing of oral solid dose pharmaceuticals. Further, it will focus on making easier to adopt continuous manufacturing by improving the quality, quantity and efficiency of production.


Market Trend
  • Augmented Pharmaceutical Industry Expenditure

Market Drivers
  • Continuous Pharmaceutical Manufacturing Reduces Manufacturing Costs for Long Term Hence It Is Mostly Preferred
  • Reduces the Risk of Human Error & Improves Quality Drives the Demand For the Continue Pharmaceutical Manufacturing

Opportunities
  • Technological Advancements Is Continuous Manufacturing Process Is Providing Opportunity for Quicker and Errorless Drug Production

Restraints
  • Limitations for Small Scale Pharmaceutical Companies

Challenges
  • High Capital Investments to Install Production Lines


Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Strategic Business Planners, Pharmaceutical Companies, Government Regulatory, Research Organizations and End-Use Industries

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Type
  • Integrated Systems
  • End to End Systems
By Application
  • API manufacturing
  • Final Drug Development
By End Use
  • Pharmaceutical Companies
  • Contract Manufacturing Companies
  • Research Institutes

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Continuous Pharmaceutical Manufacturing Reduces Manufacturing Costs for Long Term Hence It Is Mostly Preferred
      • 3.2.2. Reduces the Risk of Human Error & Improves Quality Drives the Demand For the Continue Pharmaceutical Manufacturing
    • 3.3. Market Challenges
      • 3.3.1. High Capital Investments to Install Production Lines
    • 3.4. Market Trends
      • 3.4.1. Augmented Pharmaceutical Industry Expenditure
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Pharmaceutical Continuous Manufacturing, by Type, Application, End Use and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Pharmaceutical Continuous Manufacturing (Value)
      • 5.2.1. Global Pharmaceutical Continuous Manufacturing by: Type (Value)
        • 5.2.1.1. Integrated Systems
        • 5.2.1.2. End to End Systems
      • 5.2.2. Global Pharmaceutical Continuous Manufacturing by: Application (Value)
        • 5.2.2.1. API manufacturing
        • 5.2.2.2. Final Drug Development
      • 5.2.3. Global Pharmaceutical Continuous Manufacturing by: End Use (Value)
        • 5.2.3.1. Pharmaceutical Companies
        • 5.2.3.2. Contract Manufacturing Companies
        • 5.2.3.3. Research Institutes
      • 5.2.4. Global Pharmaceutical Continuous Manufacturing Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Pharmaceutical Continuous Manufacturing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Korsch AG (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GEA Group AG (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Siemens AG (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Thermo Fisher Scientific Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Corning Life Sciences(United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Coperion GmbH (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Gebrüder Lödige Maschinenbau GmbH (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Scott Equipment Company (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Baker Perkins Ltd. (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. S K Biotek ltd (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Sturtevant, Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Pharmaceutical Continuous Manufacturing Sale, by Type, Application, End Use and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Pharmaceutical Continuous Manufacturing (Value)
      • 7.2.1. Global Pharmaceutical Continuous Manufacturing by: Type (Value)
        • 7.2.1.1. Integrated Systems
        • 7.2.1.2. End to End Systems
      • 7.2.2. Global Pharmaceutical Continuous Manufacturing by: Application (Value)
        • 7.2.2.1. API manufacturing
        • 7.2.2.2. Final Drug Development
      • 7.2.3. Global Pharmaceutical Continuous Manufacturing by: End Use (Value)
        • 7.2.3.1. Pharmaceutical Companies
        • 7.2.3.2. Contract Manufacturing Companies
        • 7.2.3.3. Research Institutes
      • 7.2.4. Global Pharmaceutical Continuous Manufacturing Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Pharmaceutical Continuous Manufacturing: by Type(USD Million)
  • Table 2. Pharmaceutical Continuous Manufacturing Integrated Systems , by Region USD Million (2015-2020)
  • Table 3. Pharmaceutical Continuous Manufacturing End to End Systems , by Region USD Million (2015-2020)
  • Table 4. Pharmaceutical Continuous Manufacturing: by Application(USD Million)
  • Table 5. Pharmaceutical Continuous Manufacturing API manufacturing , by Region USD Million (2015-2020)
  • Table 6. Pharmaceutical Continuous Manufacturing Final Drug Development , by Region USD Million (2015-2020)
  • Table 7. Pharmaceutical Continuous Manufacturing: by End Use(USD Million)
  • Table 8. Pharmaceutical Continuous Manufacturing Pharmaceutical Companies , by Region USD Million (2015-2020)
  • Table 9. Pharmaceutical Continuous Manufacturing Contract Manufacturing Companies , by Region USD Million (2015-2020)
  • Table 10. Pharmaceutical Continuous Manufacturing Research Institutes , by Region USD Million (2015-2020)
  • Table 11. South America Pharmaceutical Continuous Manufacturing, by Country USD Million (2015-2020)
  • Table 12. South America Pharmaceutical Continuous Manufacturing, by Type USD Million (2015-2020)
  • Table 13. South America Pharmaceutical Continuous Manufacturing, by Application USD Million (2015-2020)
  • Table 14. South America Pharmaceutical Continuous Manufacturing, by End Use USD Million (2015-2020)
  • Table 15. Brazil Pharmaceutical Continuous Manufacturing, by Type USD Million (2015-2020)
  • Table 16. Brazil Pharmaceutical Continuous Manufacturing, by Application USD Million (2015-2020)
  • Table 17. Brazil Pharmaceutical Continuous Manufacturing, by End Use USD Million (2015-2020)
  • Table 18. Argentina Pharmaceutical Continuous Manufacturing, by Type USD Million (2015-2020)
  • Table 19. Argentina Pharmaceutical Continuous Manufacturing, by Application USD Million (2015-2020)
  • Table 20. Argentina Pharmaceutical Continuous Manufacturing, by End Use USD Million (2015-2020)
  • Table 21. Rest of South America Pharmaceutical Continuous Manufacturing, by Type USD Million (2015-2020)
  • Table 22. Rest of South America Pharmaceutical Continuous Manufacturing, by Application USD Million (2015-2020)
  • Table 23. Rest of South America Pharmaceutical Continuous Manufacturing, by End Use USD Million (2015-2020)
  • Table 24. Asia Pacific Pharmaceutical Continuous Manufacturing, by Country USD Million (2015-2020)
  • Table 25. Asia Pacific Pharmaceutical Continuous Manufacturing, by Type USD Million (2015-2020)
  • Table 26. Asia Pacific Pharmaceutical Continuous Manufacturing, by Application USD Million (2015-2020)
  • Table 27. Asia Pacific Pharmaceutical Continuous Manufacturing, by End Use USD Million (2015-2020)
  • Table 28. China Pharmaceutical Continuous Manufacturing, by Type USD Million (2015-2020)
  • Table 29. China Pharmaceutical Continuous Manufacturing, by Application USD Million (2015-2020)
  • Table 30. China Pharmaceutical Continuous Manufacturing, by End Use USD Million (2015-2020)
  • Table 31. Japan Pharmaceutical Continuous Manufacturing, by Type USD Million (2015-2020)
  • Table 32. Japan Pharmaceutical Continuous Manufacturing, by Application USD Million (2015-2020)
  • Table 33. Japan Pharmaceutical Continuous Manufacturing, by End Use USD Million (2015-2020)
  • Table 34. India Pharmaceutical Continuous Manufacturing, by Type USD Million (2015-2020)
  • Table 35. India Pharmaceutical Continuous Manufacturing, by Application USD Million (2015-2020)
  • Table 36. India Pharmaceutical Continuous Manufacturing, by End Use USD Million (2015-2020)
  • Table 37. South Korea Pharmaceutical Continuous Manufacturing, by Type USD Million (2015-2020)
  • Table 38. South Korea Pharmaceutical Continuous Manufacturing, by Application USD Million (2015-2020)
  • Table 39. South Korea Pharmaceutical Continuous Manufacturing, by End Use USD Million (2015-2020)
  • Table 40. Taiwan Pharmaceutical Continuous Manufacturing, by Type USD Million (2015-2020)
  • Table 41. Taiwan Pharmaceutical Continuous Manufacturing, by Application USD Million (2015-2020)
  • Table 42. Taiwan Pharmaceutical Continuous Manufacturing, by End Use USD Million (2015-2020)
  • Table 43. Australia Pharmaceutical Continuous Manufacturing, by Type USD Million (2015-2020)
  • Table 44. Australia Pharmaceutical Continuous Manufacturing, by Application USD Million (2015-2020)
  • Table 45. Australia Pharmaceutical Continuous Manufacturing, by End Use USD Million (2015-2020)
  • Table 46. Rest of Asia-Pacific Pharmaceutical Continuous Manufacturing, by Type USD Million (2015-2020)
  • Table 47. Rest of Asia-Pacific Pharmaceutical Continuous Manufacturing, by Application USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Pharmaceutical Continuous Manufacturing, by End Use USD Million (2015-2020)
  • Table 49. Europe Pharmaceutical Continuous Manufacturing, by Country USD Million (2015-2020)
  • Table 50. Europe Pharmaceutical Continuous Manufacturing, by Type USD Million (2015-2020)
  • Table 51. Europe Pharmaceutical Continuous Manufacturing, by Application USD Million (2015-2020)
  • Table 52. Europe Pharmaceutical Continuous Manufacturing, by End Use USD Million (2015-2020)
  • Table 53. Germany Pharmaceutical Continuous Manufacturing, by Type USD Million (2015-2020)
  • Table 54. Germany Pharmaceutical Continuous Manufacturing, by Application USD Million (2015-2020)
  • Table 55. Germany Pharmaceutical Continuous Manufacturing, by End Use USD Million (2015-2020)
  • Table 56. France Pharmaceutical Continuous Manufacturing, by Type USD Million (2015-2020)
  • Table 57. France Pharmaceutical Continuous Manufacturing, by Application USD Million (2015-2020)
  • Table 58. France Pharmaceutical Continuous Manufacturing, by End Use USD Million (2015-2020)
  • Table 59. Italy Pharmaceutical Continuous Manufacturing, by Type USD Million (2015-2020)
  • Table 60. Italy Pharmaceutical Continuous Manufacturing, by Application USD Million (2015-2020)
  • Table 61. Italy Pharmaceutical Continuous Manufacturing, by End Use USD Million (2015-2020)
  • Table 62. United Kingdom Pharmaceutical Continuous Manufacturing, by Type USD Million (2015-2020)
  • Table 63. United Kingdom Pharmaceutical Continuous Manufacturing, by Application USD Million (2015-2020)
  • Table 64. United Kingdom Pharmaceutical Continuous Manufacturing, by End Use USD Million (2015-2020)
  • Table 65. Netherlands Pharmaceutical Continuous Manufacturing, by Type USD Million (2015-2020)
  • Table 66. Netherlands Pharmaceutical Continuous Manufacturing, by Application USD Million (2015-2020)
  • Table 67. Netherlands Pharmaceutical Continuous Manufacturing, by End Use USD Million (2015-2020)
  • Table 68. Rest of Europe Pharmaceutical Continuous Manufacturing, by Type USD Million (2015-2020)
  • Table 69. Rest of Europe Pharmaceutical Continuous Manufacturing, by Application USD Million (2015-2020)
  • Table 70. Rest of Europe Pharmaceutical Continuous Manufacturing, by End Use USD Million (2015-2020)
  • Table 71. MEA Pharmaceutical Continuous Manufacturing, by Country USD Million (2015-2020)
  • Table 72. MEA Pharmaceutical Continuous Manufacturing, by Type USD Million (2015-2020)
  • Table 73. MEA Pharmaceutical Continuous Manufacturing, by Application USD Million (2015-2020)
  • Table 74. MEA Pharmaceutical Continuous Manufacturing, by End Use USD Million (2015-2020)
  • Table 75. Middle East Pharmaceutical Continuous Manufacturing, by Type USD Million (2015-2020)
  • Table 76. Middle East Pharmaceutical Continuous Manufacturing, by Application USD Million (2015-2020)
  • Table 77. Middle East Pharmaceutical Continuous Manufacturing, by End Use USD Million (2015-2020)
  • Table 78. Africa Pharmaceutical Continuous Manufacturing, by Type USD Million (2015-2020)
  • Table 79. Africa Pharmaceutical Continuous Manufacturing, by Application USD Million (2015-2020)
  • Table 80. Africa Pharmaceutical Continuous Manufacturing, by End Use USD Million (2015-2020)
  • Table 81. North America Pharmaceutical Continuous Manufacturing, by Country USD Million (2015-2020)
  • Table 82. North America Pharmaceutical Continuous Manufacturing, by Type USD Million (2015-2020)
  • Table 83. North America Pharmaceutical Continuous Manufacturing, by Application USD Million (2015-2020)
  • Table 84. North America Pharmaceutical Continuous Manufacturing, by End Use USD Million (2015-2020)
  • Table 85. United States Pharmaceutical Continuous Manufacturing, by Type USD Million (2015-2020)
  • Table 86. United States Pharmaceutical Continuous Manufacturing, by Application USD Million (2015-2020)
  • Table 87. United States Pharmaceutical Continuous Manufacturing, by End Use USD Million (2015-2020)
  • Table 88. Canada Pharmaceutical Continuous Manufacturing, by Type USD Million (2015-2020)
  • Table 89. Canada Pharmaceutical Continuous Manufacturing, by Application USD Million (2015-2020)
  • Table 90. Canada Pharmaceutical Continuous Manufacturing, by End Use USD Million (2015-2020)
  • Table 91. Mexico Pharmaceutical Continuous Manufacturing, by Type USD Million (2015-2020)
  • Table 92. Mexico Pharmaceutical Continuous Manufacturing, by Application USD Million (2015-2020)
  • Table 93. Mexico Pharmaceutical Continuous Manufacturing, by End Use USD Million (2015-2020)
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Pharmaceutical Continuous Manufacturing: by Type(USD Million)
  • Table 106. Pharmaceutical Continuous Manufacturing Integrated Systems , by Region USD Million (2021-2026)
  • Table 107. Pharmaceutical Continuous Manufacturing End to End Systems , by Region USD Million (2021-2026)
  • Table 108. Pharmaceutical Continuous Manufacturing: by Application(USD Million)
  • Table 109. Pharmaceutical Continuous Manufacturing API manufacturing , by Region USD Million (2021-2026)
  • Table 110. Pharmaceutical Continuous Manufacturing Final Drug Development , by Region USD Million (2021-2026)
  • Table 111. Pharmaceutical Continuous Manufacturing: by End Use(USD Million)
  • Table 112. Pharmaceutical Continuous Manufacturing Pharmaceutical Companies , by Region USD Million (2021-2026)
  • Table 113. Pharmaceutical Continuous Manufacturing Contract Manufacturing Companies , by Region USD Million (2021-2026)
  • Table 114. Pharmaceutical Continuous Manufacturing Research Institutes , by Region USD Million (2021-2026)
  • Table 115. South America Pharmaceutical Continuous Manufacturing, by Country USD Million (2021-2026)
  • Table 116. South America Pharmaceutical Continuous Manufacturing, by Type USD Million (2021-2026)
  • Table 117. South America Pharmaceutical Continuous Manufacturing, by Application USD Million (2021-2026)
  • Table 118. South America Pharmaceutical Continuous Manufacturing, by End Use USD Million (2021-2026)
  • Table 119. Brazil Pharmaceutical Continuous Manufacturing, by Type USD Million (2021-2026)
  • Table 120. Brazil Pharmaceutical Continuous Manufacturing, by Application USD Million (2021-2026)
  • Table 121. Brazil Pharmaceutical Continuous Manufacturing, by End Use USD Million (2021-2026)
  • Table 122. Argentina Pharmaceutical Continuous Manufacturing, by Type USD Million (2021-2026)
  • Table 123. Argentina Pharmaceutical Continuous Manufacturing, by Application USD Million (2021-2026)
  • Table 124. Argentina Pharmaceutical Continuous Manufacturing, by End Use USD Million (2021-2026)
  • Table 125. Rest of South America Pharmaceutical Continuous Manufacturing, by Type USD Million (2021-2026)
  • Table 126. Rest of South America Pharmaceutical Continuous Manufacturing, by Application USD Million (2021-2026)
  • Table 127. Rest of South America Pharmaceutical Continuous Manufacturing, by End Use USD Million (2021-2026)
  • Table 128. Asia Pacific Pharmaceutical Continuous Manufacturing, by Country USD Million (2021-2026)
  • Table 129. Asia Pacific Pharmaceutical Continuous Manufacturing, by Type USD Million (2021-2026)
  • Table 130. Asia Pacific Pharmaceutical Continuous Manufacturing, by Application USD Million (2021-2026)
  • Table 131. Asia Pacific Pharmaceutical Continuous Manufacturing, by End Use USD Million (2021-2026)
  • Table 132. China Pharmaceutical Continuous Manufacturing, by Type USD Million (2021-2026)
  • Table 133. China Pharmaceutical Continuous Manufacturing, by Application USD Million (2021-2026)
  • Table 134. China Pharmaceutical Continuous Manufacturing, by End Use USD Million (2021-2026)
  • Table 135. Japan Pharmaceutical Continuous Manufacturing, by Type USD Million (2021-2026)
  • Table 136. Japan Pharmaceutical Continuous Manufacturing, by Application USD Million (2021-2026)
  • Table 137. Japan Pharmaceutical Continuous Manufacturing, by End Use USD Million (2021-2026)
  • Table 138. India Pharmaceutical Continuous Manufacturing, by Type USD Million (2021-2026)
  • Table 139. India Pharmaceutical Continuous Manufacturing, by Application USD Million (2021-2026)
  • Table 140. India Pharmaceutical Continuous Manufacturing, by End Use USD Million (2021-2026)
  • Table 141. South Korea Pharmaceutical Continuous Manufacturing, by Type USD Million (2021-2026)
  • Table 142. South Korea Pharmaceutical Continuous Manufacturing, by Application USD Million (2021-2026)
  • Table 143. South Korea Pharmaceutical Continuous Manufacturing, by End Use USD Million (2021-2026)
  • Table 144. Taiwan Pharmaceutical Continuous Manufacturing, by Type USD Million (2021-2026)
  • Table 145. Taiwan Pharmaceutical Continuous Manufacturing, by Application USD Million (2021-2026)
  • Table 146. Taiwan Pharmaceutical Continuous Manufacturing, by End Use USD Million (2021-2026)
  • Table 147. Australia Pharmaceutical Continuous Manufacturing, by Type USD Million (2021-2026)
  • Table 148. Australia Pharmaceutical Continuous Manufacturing, by Application USD Million (2021-2026)
  • Table 149. Australia Pharmaceutical Continuous Manufacturing, by End Use USD Million (2021-2026)
  • Table 150. Rest of Asia-Pacific Pharmaceutical Continuous Manufacturing, by Type USD Million (2021-2026)
  • Table 151. Rest of Asia-Pacific Pharmaceutical Continuous Manufacturing, by Application USD Million (2021-2026)
  • Table 152. Rest of Asia-Pacific Pharmaceutical Continuous Manufacturing, by End Use USD Million (2021-2026)
  • Table 153. Europe Pharmaceutical Continuous Manufacturing, by Country USD Million (2021-2026)
  • Table 154. Europe Pharmaceutical Continuous Manufacturing, by Type USD Million (2021-2026)
  • Table 155. Europe Pharmaceutical Continuous Manufacturing, by Application USD Million (2021-2026)
  • Table 156. Europe Pharmaceutical Continuous Manufacturing, by End Use USD Million (2021-2026)
  • Table 157. Germany Pharmaceutical Continuous Manufacturing, by Type USD Million (2021-2026)
  • Table 158. Germany Pharmaceutical Continuous Manufacturing, by Application USD Million (2021-2026)
  • Table 159. Germany Pharmaceutical Continuous Manufacturing, by End Use USD Million (2021-2026)
  • Table 160. France Pharmaceutical Continuous Manufacturing, by Type USD Million (2021-2026)
  • Table 161. France Pharmaceutical Continuous Manufacturing, by Application USD Million (2021-2026)
  • Table 162. France Pharmaceutical Continuous Manufacturing, by End Use USD Million (2021-2026)
  • Table 163. Italy Pharmaceutical Continuous Manufacturing, by Type USD Million (2021-2026)
  • Table 164. Italy Pharmaceutical Continuous Manufacturing, by Application USD Million (2021-2026)
  • Table 165. Italy Pharmaceutical Continuous Manufacturing, by End Use USD Million (2021-2026)
  • Table 166. United Kingdom Pharmaceutical Continuous Manufacturing, by Type USD Million (2021-2026)
  • Table 167. United Kingdom Pharmaceutical Continuous Manufacturing, by Application USD Million (2021-2026)
  • Table 168. United Kingdom Pharmaceutical Continuous Manufacturing, by End Use USD Million (2021-2026)
  • Table 169. Netherlands Pharmaceutical Continuous Manufacturing, by Type USD Million (2021-2026)
  • Table 170. Netherlands Pharmaceutical Continuous Manufacturing, by Application USD Million (2021-2026)
  • Table 171. Netherlands Pharmaceutical Continuous Manufacturing, by End Use USD Million (2021-2026)
  • Table 172. Rest of Europe Pharmaceutical Continuous Manufacturing, by Type USD Million (2021-2026)
  • Table 173. Rest of Europe Pharmaceutical Continuous Manufacturing, by Application USD Million (2021-2026)
  • Table 174. Rest of Europe Pharmaceutical Continuous Manufacturing, by End Use USD Million (2021-2026)
  • Table 175. MEA Pharmaceutical Continuous Manufacturing, by Country USD Million (2021-2026)
  • Table 176. MEA Pharmaceutical Continuous Manufacturing, by Type USD Million (2021-2026)
  • Table 177. MEA Pharmaceutical Continuous Manufacturing, by Application USD Million (2021-2026)
  • Table 178. MEA Pharmaceutical Continuous Manufacturing, by End Use USD Million (2021-2026)
  • Table 179. Middle East Pharmaceutical Continuous Manufacturing, by Type USD Million (2021-2026)
  • Table 180. Middle East Pharmaceutical Continuous Manufacturing, by Application USD Million (2021-2026)
  • Table 181. Middle East Pharmaceutical Continuous Manufacturing, by End Use USD Million (2021-2026)
  • Table 182. Africa Pharmaceutical Continuous Manufacturing, by Type USD Million (2021-2026)
  • Table 183. Africa Pharmaceutical Continuous Manufacturing, by Application USD Million (2021-2026)
  • Table 184. Africa Pharmaceutical Continuous Manufacturing, by End Use USD Million (2021-2026)
  • Table 185. North America Pharmaceutical Continuous Manufacturing, by Country USD Million (2021-2026)
  • Table 186. North America Pharmaceutical Continuous Manufacturing, by Type USD Million (2021-2026)
  • Table 187. North America Pharmaceutical Continuous Manufacturing, by Application USD Million (2021-2026)
  • Table 188. North America Pharmaceutical Continuous Manufacturing, by End Use USD Million (2021-2026)
  • Table 189. United States Pharmaceutical Continuous Manufacturing, by Type USD Million (2021-2026)
  • Table 190. United States Pharmaceutical Continuous Manufacturing, by Application USD Million (2021-2026)
  • Table 191. United States Pharmaceutical Continuous Manufacturing, by End Use USD Million (2021-2026)
  • Table 192. Canada Pharmaceutical Continuous Manufacturing, by Type USD Million (2021-2026)
  • Table 193. Canada Pharmaceutical Continuous Manufacturing, by Application USD Million (2021-2026)
  • Table 194. Canada Pharmaceutical Continuous Manufacturing, by End Use USD Million (2021-2026)
  • Table 195. Mexico Pharmaceutical Continuous Manufacturing, by Type USD Million (2021-2026)
  • Table 196. Mexico Pharmaceutical Continuous Manufacturing, by Application USD Million (2021-2026)
  • Table 197. Mexico Pharmaceutical Continuous Manufacturing, by End Use USD Million (2021-2026)
  • Table 198. Research Programs/Design for This Report
  • Table 199. Key Data Information from Secondary Sources
  • Table 200. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Pharmaceutical Continuous Manufacturing: by Type USD Million (2015-2020)
  • Figure 5. Global Pharmaceutical Continuous Manufacturing: by Application USD Million (2015-2020)
  • Figure 6. Global Pharmaceutical Continuous Manufacturing: by End Use USD Million (2015-2020)
  • Figure 7. South America Pharmaceutical Continuous Manufacturing Share (%), by Country
  • Figure 8. Asia Pacific Pharmaceutical Continuous Manufacturing Share (%), by Country
  • Figure 9. Europe Pharmaceutical Continuous Manufacturing Share (%), by Country
  • Figure 10. MEA Pharmaceutical Continuous Manufacturing Share (%), by Country
  • Figure 11. North America Pharmaceutical Continuous Manufacturing Share (%), by Country
  • Figure 12. Global Pharmaceutical Continuous Manufacturing share by Players 2020 (%)
  • Figure 13. Global Pharmaceutical Continuous Manufacturing share by Players (Top 3) 2020(%)
  • Figure 14. Global Pharmaceutical Continuous Manufacturing share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Korsch AG (Germany) Revenue, Net Income and Gross profit
  • Figure 17. Korsch AG (Germany) Revenue: by Geography 2020
  • Figure 18. GEA Group AG (Germany) Revenue, Net Income and Gross profit
  • Figure 19. GEA Group AG (Germany) Revenue: by Geography 2020
  • Figure 20. Siemens AG (Germany) Revenue, Net Income and Gross profit
  • Figure 21. Siemens AG (Germany) Revenue: by Geography 2020
  • Figure 22. Thermo Fisher Scientific Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Thermo Fisher Scientific Inc. (United States) Revenue: by Geography 2020
  • Figure 24. Corning Life Sciences(United States) Revenue, Net Income and Gross profit
  • Figure 25. Corning Life Sciences(United States) Revenue: by Geography 2020
  • Figure 26. Coperion GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 27. Coperion GmbH (Germany) Revenue: by Geography 2020
  • Figure 28. Gebrüder Lödige Maschinenbau GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 29. Gebrüder Lödige Maschinenbau GmbH (Germany) Revenue: by Geography 2020
  • Figure 30. Scott Equipment Company (United States) Revenue, Net Income and Gross profit
  • Figure 31. Scott Equipment Company (United States) Revenue: by Geography 2020
  • Figure 32. Baker Perkins Ltd. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. Baker Perkins Ltd. (United Kingdom) Revenue: by Geography 2020
  • Figure 34. S K Biotek ltd (United States) Revenue, Net Income and Gross profit
  • Figure 35. S K Biotek ltd (United States) Revenue: by Geography 2020
  • Figure 36. Sturtevant, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Sturtevant, Inc. (United States) Revenue: by Geography 2020
  • Figure 38. Global Pharmaceutical Continuous Manufacturing: by Type USD Million (2021-2026)
  • Figure 39. Global Pharmaceutical Continuous Manufacturing: by Application USD Million (2021-2026)
  • Figure 40. Global Pharmaceutical Continuous Manufacturing: by End Use USD Million (2021-2026)
  • Figure 41. South America Pharmaceutical Continuous Manufacturing Share (%), by Country
  • Figure 42. Asia Pacific Pharmaceutical Continuous Manufacturing Share (%), by Country
  • Figure 43. Europe Pharmaceutical Continuous Manufacturing Share (%), by Country
  • Figure 44. MEA Pharmaceutical Continuous Manufacturing Share (%), by Country
  • Figure 45. North America Pharmaceutical Continuous Manufacturing Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Korsch AG (Germany)
  • GEA Group AG (Germany)
  • Siemens AG (Germany)
  • Thermo Fisher Scientific Inc. (United States)
  • Corning Life Sciences(United States)
  • Coperion GmbH (Germany)
  • Gebrüder Lödige Maschinenbau GmbH (Germany)
  • Scott Equipment Company (United States)
  • Baker Perkins Ltd. (United Kingdom)
  • S K Biotek ltd (United States)
  • Sturtevant, Inc. (United States)
Additional players considered in the study are as follows:
Continuus Pharmaceutical (United States) , Glatt GmbH (Germany)
Select User Access Type

Key Highlights of Report


Mar 2021 231 Pages 84 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Pharmaceutical Continuous Manufacturing Quantitative research analysis
Global Pharmaceutical Continuous Manufacturing Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Korsch AG (Germany), GEA Group AG (Germany), Siemens AG (Germany), Thermo Fisher Scientific Inc. (United States), Corning Life Sciences(United States), Coperion GmbH (Germany), Gebrüder Lödige Maschinenbau GmbH (Germany), Scott Equipment Company (United States), Baker Perkins Ltd. (United Kingdom), S K Biotek ltd (United States) and Sturtevant, Inc. (United States) etc.
Analysts at AMA estimates Pharmaceutical Continuous Manufacturing Market to reach USDXXX by 2026.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Know More About Global Pharmaceutical Continuous Manufacturing Report?

Have a Query? Click Here

Other Related Reports

Metagenomics Sequencing Comprehensive Study by Application (Infectious Disease Diagnosis, Environmental Remediation, Gut Microbe Characterization, Biofuel, Others), Technology (Sequencing, Bioinforma...
$ 3800
Atosiban Comprehensive Study by Type (Injection, Concentrate), Application (Suppression of Preterm Labour, Others), End User (Hospitals, Clinics, Others) Players and Region - Global Market Outlook to...
$ 3500
Pathogen Identification and Treatment Comprehensive Study by Type (Denaturation, Annealing, Amplification, Detection), Application (Biodefense, Animal Health Care, Food Safety, Diagnostics, Pathology...
$ 3350
Pulmonary Surfactant Comprehensive Study by Type (Synthetic Pulmonary Surfactants, Animal Derived Surfactants), Application (Hospital, Laboratory, Others), End User (Adults, Children) Players and Reg...
$ 3500
Cancer Supportive Care Drugs Comprehensive Study by Application (Chemotherapy Therapy, Radiation Therapy), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Compounding Pharmacies), Cance...
$ 3750
Botanical and Plant Derived Drugs Comprehensive Study by Type (Tablets, Capsules, Pills, Injections), Application (Central Nervous System, Cardiovascular Diseases, Infectious Diseases, Respiratory Di...
$ 3750